| Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference THJ Goodship, HT Cook, F Fakhouri, FC Fervenza, V Frémeaux-Bacchi, ... Kidney international 91 (3), 539-551, 2017 | 648 | 2017 |
| Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies A Servais, LH Noël, LT Roumenina, M Le Quintrec, S Ngo, ... Kidney international 82 (4), 454-464, 2012 | 590 | 2012 |
| Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome M Lemaire, V Frémeaux-Bacchi, F Schaefer, M Choi, WH Tang, ... Nature genetics 45 (5), 531-536, 2013 | 516 | 2013 |
| Endothelium structure and function in kidney health and disease N Jourde-Chiche, F Fakhouri, L Dou, J Bellien, S Burtey, M Frimat, ... Nature Reviews Nephrology 15 (2), 87-108, 2019 | 370 | 2019 |
| Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome A Servais, V Frémeaux-Bacchi, M Lequintrec, R Salomon, J Blouin, ... Journal of medical genetics 44 (3), 193-199, 2007 | 368 | 2007 |
| Clinical features of anti-factor H autoantibody–associated hemolytic uremic syndrome MA Dragon-Durey, SK Sethi, A Bagga, C Blanc, J Blouin, B Ranchin, ... Journal of the American Society of Nephrology 21 (12), 2180-2187, 2010 | 342 | 2010 |
| Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation J Zuber, M Le Quintrec, S Krid, C Bertoye, V Gueutin, A Lahoche, ... American Journal of Transplantation 12 (12), 3337-3354, 2012 | 306 | 2012 |
| Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome M Le Quintrec, J Zuber, B Moulin, N Kamar, M Jablonski, A Lionet, ... American Journal of Transplantation 13 (3), 663-675, 2013 | 285 | 2013 |
| An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants S Caillard, D Anglicheau, M Matignon, A Durrbach, C Greze, L Frimat, ... Kidney international 98 (6), 1549-1558, 2020 | 265 | 2020 |
| New insights into postrenal transplant hemolytic uremic syndrome J Zuber, M Le Quintrec, R Sberro-Soussan, C Loirat, V Frémeaux-Bacchi, ... Nature Reviews Nephrology 7 (1), 23-35, 2011 | 245 | 2011 |
| Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation M Le Quintrec, A Lionet, N Kamar, A Karras, S Barbier, M Buchler, ... American Journal of Transplantation 8 (8), 1694-1701, 2008 | 204 | 2008 |
| Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches M Riedl, F Fakhouri, M Le Quintrec, DG Noone, TC Jungraithmayr, ... Seminars in thrombosis and hemostasis 40 (04), 444-464, 2014 | 161 | 2014 |
| Herbs and the kidney CI Bagnis, G Deray, A Baumelou, M Le Quintrec, JL Vanherweghem American journal of kidney diseases 44 (1), 1-11, 2004 | 154 | 2004 |
| Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy S Chauvet, V Frémeaux-Bacchi, F Petitprez, A Karras, L Daniel, S Burtey, ... Blood, The Journal of the American Society of Hematology 129 (11), 1437-1447, 2017 | 151 | 2017 |
| The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, ... Kidney international 97 (6), 1287-1296, 2020 | 142 | 2020 |
| Anti–Factor H Autoantibodies in C3 Glomerulopathies and in atypical hemolytic uremic syndrome: One target, two diseases C Blanc, SK Togarsimalemath, S Chauvet, M Le Quintrec, B Moulin, ... The Journal of Immunology 194 (11), 5129-5138, 2015 | 130 | 2015 |
| Eculizumab for treatment of rapidly progressive C3 glomerulopathy M Le Quintrec, A Lionet, C Kandel, F Bourdon, V Gnemmi, M Colombat, ... American Journal of Kidney Diseases 65 (3), 484-489, 2015 | 120 | 2015 |
| Patterns of clinical response to eculizumab in patients with C3 glomerulopathy M Le Quintrec, AL Lapeyraque, A Lionet, AL Sellier-Leclerc, Y Delmas, ... American Journal of Kidney Diseases 72 (1), 84-92, 2018 | 118 | 2018 |
| Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study F Fakhouri, M Fila, A Hummel, D Ribes, AL Sellier-Leclerc, S Ville, ... Blood, The Journal of the American Society of Hematology 137 (18), 2438-2449, 2021 | 116 | 2021 |
| Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation J Zuber, M Le Quintrec, H Morris, V Frémeaux-Bacchi, C Loirat, ... Transplantation reviews 27 (4), 117-125, 2013 | 107 | 2013 |
Lubka RoumeninaINSERM UMRS1138, InC2 Lab Inflammation, Complement and CancerVerified email at sorbonne-universite.fr
